0.64
+0(+0.00%)
Currency In USD
| Previous Close | 0.64 |
| Open | 0.64 |
| Day High | 0.65 |
| Day Low | 0.63 |
| 52-Week High | 1.29 |
| 52-Week Low | 0.2 |
| Volume | 212,068 |
| Average Volume | 964,973 |
| Market Cap | 66.43M |
| PE | -1.14 |
| EPS | -0.56 |
| Moving Average 50 Days | 0.58 |
| Moving Average 200 Days | 0.53 |
| Change | 0 |
If you invested $1000 in Unicycive Therapeutics, Inc. (UNCY) since IPO date, it would be worth $128 as of April 26, 2025 at a share price of $0.64. Whereas If you bought $1000 worth of Unicycive Therapeutics, Inc. (UNCY) shares 3 years ago, it would be worth $640.64 as of April 26, 2025 at a share price of $0.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
GlobeNewswire Inc.
Apr 10, 2025 12:00 PM GMT
– Patient-reported outcomes from Phase 2 trial of oxylanthanum carbonate (OLC) demonstrate high patient satisfaction with OLC compared to their prior phosphate lowering therapy – – Findings from a patient survey conducted in partnership with the Nati
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Apr 01, 2025 11:00 AM GMT
LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executi
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
GlobeNewswire Inc.
Mar 13, 2025 11:00 AM GMT
LOS ALTOS, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it will present patient reported o